33. Ryan Cross, “The redemption of James Wilson.” Chemical & Engineering News, September 2019, https://cen.acs.org/business/The-redemption-of-James-Wilson-gene-therapy-pioneer/97/i36.
34. David Schaffer, TRI-CON, San Francisco, March 2, 2019.
35. Julianna LeMieux, “Going Viraclass="underline" The Next Generation of AAV Vectors,” Genetic Engineering & Biotechnology News, September 3, 2019, https://www.genengnews.com/insights/going-viral-the-next-generation-of-aav-vectors/.
36. Editorial, “Gene therapy deserves a fresh chance,” Nature 461, (2009): 1173, https://www.nature.com/articles/4611173a.
37. Melinda Wenner, “Gene therapy: An interview with an unfortunate pioneer,” Scientific American, September 1, 2009, https://www.scientificamerican.com/article/gene-therapy-an-interview/?redirect=1.
38. Carl Zimmer, “Gene therapy emerges from disgrace to be the next big thing, again,” WIRED, August 13, 2013, https://www.wired.com/2013/08/the-fall-and-rise-of-gene-therapy-2/.
39. JapanPrize, “2015 Japan Prize Commemorative Lecture: Dr. Theodore Friedmann & Prof. Alain Fischer,” YouTube video, 1:07:56, last viewed June 30, 2020, https://youtu.be/Z5SLxpPLxcwe.
Chapter 11: Overnight Success
1. Ricki Lewis, “Luxturna: A giant step forward for blindness gene therapy—a conversation with Dr. Kathy High,” DNA Science Blog, July 20, 2017, https://blogs.plos.org/dnascience/2017/07/20/luxturna-a-giant-step-forward-for-blindness-gene-therapy-a-conversation-with-dr-kathy-high/.
2. David Dobbs, “Why there’s new hope about ending blindness,” National Geographic, September 2016, https://www.nationalgeographic.com/magazine/2016/09/blindness-treatment-medical-science-cures/.
3. ASGCT, “Seeing the Light with Retinal Gene Therapy: From Fantasy to Reality—Jean Bennett,” YouTube video, 45:37, last viewed June 30, 2020, https://youtu.be/jDdFmBxNfUE.
4. J. M. Wilson, “Interview with Jean Bennett, MD, PhD,” Human Gene Therapy 29, (2018): 7–9, https://doi.org/10.1089/humc.2018.29032.int.
5. A. W. Taylor, “Ocular immune privilege,” Eye 23, (2009): 1885–1889, https://www.nature.com/articles/eye2008382.
6. Jean Bennett, “My Career Path for Developing Gene Therapy for Blinding Diseases: The Importance of Mentors, Collaborators, and Opportunities,” Human Gene Therapy 25, (2014): 663–670, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137328/.
7. J. M. Wilson, “Interview with Jean Bennett, MD, PhD,” Human Gene Therapy 29, (2018): 7–9, https://doi.org/10.1089/humc.2018.29032.int.
8. A. Maguire et al., “Safety and efficacy of gene transfer for Leber’s Congenital Amaurosis,” New England Journal of Medicine 358, (2008): 2240–2248, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829748/.
9. J. Bennett et al., “Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial,” Lancet 388, (2016): 661–672, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351775/.
10. Sharon Begley, “Out of prison, the ‘father of gene therapy’ faces a harsh reality: a tarnished legacy and an ankle monitor,” STAT, July 23, 2018, https://www.statnews.com/2018/07/23/w-french-anderson-father-of-gene-therapy/.
11. David Schaffer, TRI-CON conference, San Francisco, March 2, 2019.
12. S. Cannon, “Sickle cell disease advocate & precision medicine leader remembered,” Black Doctor, April 8, 2016, https://blackdoctor.org/my-story-any-day-without-pain-is-a-good-day/.
13. M. Friend, “Shakir Cannon, patient advocate,” CRISPR Journal 1, (2018): 24–25, https://www.liebertpub.com/doi/10.1089/crispr.2018.29005.mfr.
14. D. Shriner and C. N. Rotimi, “Whole-genome-sequence-based haplotypes reveal single origin of the sickle allele during the Holocene Wet Phase,” American Journal of Human Genetics 102, (2018): 547–556, https://www.cell.com/ajhg/fulltext/S0002-9297(18)30048-X.
15. T. L. Savitt and M. F. Goldberg, “Herrick’s 1910 case report of sickle cell anemia,” Journal of the American Medical Association 261, (1989): 266–271, https://doi.org/10.1001/jama.1989.03420020120042.
16. Editorial, “Sickle cell anemia, a race specific disease,” Journal of the American Medical Association 133, (1947): 33–34, https://jamanetwork.com/journals/jama/article-abstract/290758.
17. A. C. Allison, “Two lessons from the interface of genetics and medicine,” Genetics 166, (2004): 1591–1599, http://www.genetics.org/content/genetics/166/4/1591.full.pdf.
18. V. M. Ingram, “Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin,” Nature 180, (1957): 326–328, https://www.nature.com/articles/180326a0.
19. J. Lapook, “Could gene therapy cure sickle cell anemia?,” 60 Minutes, March 10, 2019, https://www.cbsnews.com/news/could-gene-therapy-cure-sickle-cell-anemia-60-minutes/.
20. J-A. Ribeil et al., “Gene therapy in a patient with sickle cell disease,” New England Journal of Medicine 376, (2017): 848–855, https://www.nejm.org/doi/full/10.1056/NEJMoa1609677.
21. J. Lapook, “Could gene therapy cure sickle cell anemia?,” 60 Minutes, March 10, 2019, https://www.cbsnews.com/news/could-gene-therapy-cure-sickle-cell-anemia-60-minutes/.